View ValuationDocMorris 将来の成長Future 基準チェック /16DocMorris利益と収益がそれぞれ年間65.3%と9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-16% 76.9%なると予測されています。主要情報65.3%収益成長率76.90%EPS成長率Consumer Retailing 収益成長9.0%収益成長率9.0%将来の株主資本利益率-15.98%アナリストカバレッジGood最終更新日25 Apr 2026今後の成長に関する最新情報お知らせ • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.お知らせ • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.Reported Earnings • Mar 19Full year 2025 earnings released: CHF3.47 loss per share (vs CHF8.25 loss in FY 2024)Full year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in the United Kingdom.New Risk • Jan 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF28m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change).お知らせ • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Consumer Retailing industry in the United Kingdom.お知らせ • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights Offeringお知らせ • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issueNew Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF93m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years).Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026お知らせ • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.お知らせ • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.New Risk • Jan 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF17m net loss in 3 years).Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).New Risk • Aug 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).お知らせ • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Share price has been volatile over the past 3 months (8.0% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF969.5m (up 4.1% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).New Risk • Oct 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change).お知らせ • Sep 22+ 2 more updatesDocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024DocMorris AG announced that they will report fiscal year 2023 results on Mar 21, 2024New Risk • Aug 28New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF344k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF344k net loss in 3 years). Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding).Reported Earnings • Aug 20First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.お知らせ • May 05Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG . Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees.お知らせ • Feb 03Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Reported Earnings • Aug 19First half 2022 earnings released: CHF8.29 loss per share (vs CHF8.03 loss in 1H 2021)First half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Over the next year, revenue is forecast to grow 15%, compared to a 5.8% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.お知らせ • Jul 14+ 2 more updatesZur Rose Group AG, Annual General Meeting, May 04, 2023Zur Rose Group AG, Annual General Meeting, May 04, 2023, at 17:00 Central European Standard Time.Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Reported Earnings • Aug 21First half 2021 earnings released: CHF8.03 loss per share (vs CHF6.03 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF839.8m (up 20% from 1H 2020). Net loss: CHF77.0m (loss widened 47% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.Breakeven Date Change • Jun 13No longer forecast to breakevenThe 9 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF14.2m in 2023.Executive Departure • May 04Non-Executive Director has left the companyOn the 29th of April, Tobias Hartmann's tenure as Non-Executive Director ended after 1.9 years in the role. As of December 2020, Tobias personally held 394.00 shares (CHF110k worth at the time). Tobias is the only executive to leave the company over the last 12 months.Reported Earnings • Apr 10Full year 2020 earnings released: CHF14.95 loss per share (vs CHF6.04 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.7m (loss widened 159% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.6m (loss widened 159% from FY 2019).Is New 90 Day High Low • Feb 07New 90-day high: CHF465The company is up 71% from its price of CHF273 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,030 per share.Is New 90 Day High Low • Jan 22New 90-day high: CHF410The company is up 74% from its price of CHF235 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: CHF286The company is up 27% from its price of CHF226 on 07 October 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Dec 07New 90-day low: CHF124The company is down 42% from its price of CHF213 on 08 September 2020. The British market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 07New 90-day low: CHF124The company is down 53% from its price of CHF262 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF31.15 per share.お知らせ • Aug 19Zur Rose Group AG to Report Fiscal Year 2020 Results on Mar 18, 2021Zur Rose Group AG announced that they will report fiscal year 2020 results on Mar 18, 2021お知らせ • Aug 18Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de.Zur Rose Group AG (SWX:ROSE) agreed to acquire AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on June 26, 2020. AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH formed the Mail-order and Diabetes Activities of Apotal Group. The acquisition is financed from available cash and up to 60% of the purchase price by issuing new shares funded from the authorized and conditional capital. As part of the transaction, Heinz-Peter Fichter will become a shareholder and future consultant of Zur Rose Group, Henning Fichter will be the managing director of the diabetes division and 1.1 million active customers will be transferred to Zur Rose subject to giving their consent. The transaction is subject to approval by the German Federal Cartel Office and expected to close in third quarter of 2020. Johannes H. Lucas of ACXIT Capital Partners acted as financial advisor to Zur Rose. Klaus Krink, Sönke Storch, Björn Schallock, Albrecht von Bismarck, Jörn Karall and Stephan Weber of Ebner Stolz acted as legal advisor and Alvarez & Marsal Securities, LLC provided due diligence to Zur Rose. Christoph Smile, Jochen Lux, Boris Alles, Heralt Hug, Jörn Witt, Susanne Pech, Dirk Schauer, Martin Mohr and Rolf Hempel of CMS Germany and Daniel Jenny of CMS Switzerland acted as legal advisor to Heinz-Peter Fichter, founder of Apotal Group and other partners. FERBER & CO. GmbH acted as financial advisor to Apotal Group and Heinz-Peter Fichter. Clemens Krämer of Dorn Krämer & Partner acted as legal advisor for Zur Rose. Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on August 17, 2020. For payment of the share portion of the purchase price, Zur Rose issued 0.13 million shares.お知らせ • Jul 18+ 1 more updateZur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million.Zur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million. Security Name: Shares Security Type: Common Stock Securities Offered: 740,823 Price\Range: CHF 287 Transaction Features: Subsequent Direct Listing業績と収益の成長予測LSE:0RRB - アナリストの将来予測と過去の財務データ ( )CHF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,463-23-1830612/31/20271,369-48-35-2812/31/20261,218-84-71-45612/31/20251,124-134-116-89N/A9/30/20251,093-128-108-80N/A6/30/20251,062-121-99-71N/A3/31/20251,052-114-93-64N/A12/31/20241,017-97-55-27N/A9/30/20241,010-97-75-45N/A6/30/20241,003-97-95-63N/A3/31/2024984-97-88-57N/A12/31/2023969-118-119-87N/A9/30/2023934-132-124-90N/A6/30/2023899-146-129-93N/A3/31/2023915-158-136-95N/A12/31/2022931-171-144-97N/A9/30/20221,156-202-178-126N/A6/30/20221,381-232-212-155N/A3/31/20221,554-229-203-143N/A12/31/20211,727-226-194-131N/A9/30/20211,673-193-155-87N/A6/30/20211,619-160-116-43N/A3/31/20211,548-148-122-55N/A12/31/20201,477-136-127-68N/A9/30/20201,431-112-138-88N/A6/30/20201,385-88-149-108N/A3/31/20201,370-70-137-95N/A12/31/20191,356-52-124-83N/A9/30/20191,314-45N/AN/AN/A6/30/20191,272-39N/A-35N/A3/31/20191,240-39N/A-34N/A12/31/20181,207-39N/A-33N/A9/30/20181,166-37N/AN/AN/A6/30/20181,125-36N/A-30N/A3/31/20181,061-36N/AN/AN/A12/31/2017990-36N/A-22N/A9/30/2017953-34N/A-21N/A6/30/2017915-31N/A-21N/A3/31/2017900-21N/AN/AN/A12/31/2016884-13N/A-14N/A9/30/2016873-4N/AN/AN/A6/30/20168616N/AN/AN/A3/31/20168474N/AN/AN/A12/31/20158383N/A19N/A9/30/20158574N/AN/AN/A6/30/20158755N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0RRB今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0RRB今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 0RRB今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0RRBの収益 ( 9% ) UK市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: 0RRBの収益 ( 9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0RRB 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 02:58終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DocMorris AG 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19 アナリスト機関Volker BosseBaader Helvea Equity ResearchSarah RobertsBarclaysGuillaume GallandBarclays16 その他のアナリストを表示
お知らせ • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.
お知らせ • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.
Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.
Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
お知らせ • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.
Reported Earnings • Mar 19Full year 2025 earnings released: CHF3.47 loss per share (vs CHF8.25 loss in FY 2024)Full year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in the United Kingdom.
New Risk • Jan 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF28m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change).
お知らせ • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.
Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Consumer Retailing industry in the United Kingdom.
お知らせ • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights Offering
お知らせ • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issue
New Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF93m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years).
Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026
お知らせ • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.
お知らせ • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.
Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.
New Risk • Jan 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF17m net loss in 3 years).
Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).
New Risk • Aug 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).
お知らせ • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025
New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Share price has been volatile over the past 3 months (8.0% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF969.5m (up 4.1% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
New Risk • Oct 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change).
お知らせ • Sep 22+ 2 more updatesDocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024DocMorris AG announced that they will report fiscal year 2023 results on Mar 21, 2024
New Risk • Aug 28New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF344k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF344k net loss in 3 years). Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding).
Reported Earnings • Aug 20First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
お知らせ • May 05Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG . Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees.
お知らせ • Feb 03Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.
Reported Earnings • Aug 19First half 2022 earnings released: CHF8.29 loss per share (vs CHF8.03 loss in 1H 2021)First half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Over the next year, revenue is forecast to grow 15%, compared to a 5.8% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 14+ 2 more updatesZur Rose Group AG, Annual General Meeting, May 04, 2023Zur Rose Group AG, Annual General Meeting, May 04, 2023, at 17:00 Central European Standard Time.
Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.
Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Reported Earnings • Aug 21First half 2021 earnings released: CHF8.03 loss per share (vs CHF6.03 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF839.8m (up 20% from 1H 2020). Net loss: CHF77.0m (loss widened 47% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
Breakeven Date Change • Jun 13No longer forecast to breakevenThe 9 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF14.2m in 2023.
Executive Departure • May 04Non-Executive Director has left the companyOn the 29th of April, Tobias Hartmann's tenure as Non-Executive Director ended after 1.9 years in the role. As of December 2020, Tobias personally held 394.00 shares (CHF110k worth at the time). Tobias is the only executive to leave the company over the last 12 months.
Reported Earnings • Apr 10Full year 2020 earnings released: CHF14.95 loss per share (vs CHF6.04 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.7m (loss widened 159% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.6m (loss widened 159% from FY 2019).
Is New 90 Day High Low • Feb 07New 90-day high: CHF465The company is up 71% from its price of CHF273 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,030 per share.
Is New 90 Day High Low • Jan 22New 90-day high: CHF410The company is up 74% from its price of CHF235 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: CHF286The company is up 27% from its price of CHF226 on 07 October 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Dec 07New 90-day low: CHF124The company is down 42% from its price of CHF213 on 08 September 2020. The British market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 07New 90-day low: CHF124The company is down 53% from its price of CHF262 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF31.15 per share.
お知らせ • Aug 19Zur Rose Group AG to Report Fiscal Year 2020 Results on Mar 18, 2021Zur Rose Group AG announced that they will report fiscal year 2020 results on Mar 18, 2021
お知らせ • Aug 18Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de.Zur Rose Group AG (SWX:ROSE) agreed to acquire AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on June 26, 2020. AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH formed the Mail-order and Diabetes Activities of Apotal Group. The acquisition is financed from available cash and up to 60% of the purchase price by issuing new shares funded from the authorized and conditional capital. As part of the transaction, Heinz-Peter Fichter will become a shareholder and future consultant of Zur Rose Group, Henning Fichter will be the managing director of the diabetes division and 1.1 million active customers will be transferred to Zur Rose subject to giving their consent. The transaction is subject to approval by the German Federal Cartel Office and expected to close in third quarter of 2020. Johannes H. Lucas of ACXIT Capital Partners acted as financial advisor to Zur Rose. Klaus Krink, Sönke Storch, Björn Schallock, Albrecht von Bismarck, Jörn Karall and Stephan Weber of Ebner Stolz acted as legal advisor and Alvarez & Marsal Securities, LLC provided due diligence to Zur Rose. Christoph Smile, Jochen Lux, Boris Alles, Heralt Hug, Jörn Witt, Susanne Pech, Dirk Schauer, Martin Mohr and Rolf Hempel of CMS Germany and Daniel Jenny of CMS Switzerland acted as legal advisor to Heinz-Peter Fichter, founder of Apotal Group and other partners. FERBER & CO. GmbH acted as financial advisor to Apotal Group and Heinz-Peter Fichter. Clemens Krämer of Dorn Krämer & Partner acted as legal advisor for Zur Rose. Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on August 17, 2020. For payment of the share portion of the purchase price, Zur Rose issued 0.13 million shares.
お知らせ • Jul 18+ 1 more updateZur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million.Zur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million. Security Name: Shares Security Type: Common Stock Securities Offered: 740,823 Price\Range: CHF 287 Transaction Features: Subsequent Direct Listing